Integrative multiomic profiling of cfDNA methylation and EV-miRNAs identifies immunotherapy-outcome molecular subtypes in NSCLC.

J Immunother Cancer · 2026 · PMC12815181 · PMID 41545302

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

approached significancep=0.06so close (0.05 < p ≤ 0.1)

Survival analysis revealed significant separation, log-rank p<0.05: MDC-T2 projected onto T1 distinguished patients by both OS ( figure 5D ) and PFS ( online supplemental figure S5B ), and T3 projection maintained significance for OS and approached significance for PFS (p=0.06).

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.